A Case of Rapid Progressive Neurosyphilis in Patient with Ankylosing Spondylitis Who Is Treating Anti-interleukin 17A Monoclonal Antibody, Secukinumab

Han-ki Park; Yong-sun Kim; Sang Jin Lee

대한류마티스학회 Journal of Rheumatic Diseases A Case of Rapid Progressive Neurosyphilis in Patient with Ankylosing Spondylitis Who Is Treating Anti-interleukin 17A Monoclonal Antibody, Secukinumab

Accredited SCOPUS

( Sang Jin Lee ) , ( Han-ki Park ) , ( Yong-sun Kim )

대한류마티스학회 2019.10

Journal of Rheumatic Diseases vol. 26 iss. 4 278-281(4pages)

UCI I410-ECN-0102-2021-500-000180713

More

Cite Copy URL Bookshelf

This article is 4 pages or less.

Abstract

Anti-interleukin 17A agent, secukinumab is remarkably effective for treating patients with ankylosing spondylitis. However, the main safety concern of secukinumab is an increased risk of infection. Generally, neurosyphilis occurs a few years after the pri-mary syphilitic infection. Rare cases of progressing to neurosyphilis with a much lower latency were reported. We report a case of rapid progressive neurosyphilis involving hearing loss in both ears in a patient with ankylosing spondylitis who was treated with secukinumab. (J Rheum Dis 2019;26:278-281)

Keywords

Ankylosing spondylitis

Interleukin 17A

Neurosyphilis

Table of Contents

INTRODUCTION
CASE REPORT
DISCUSSION
SUMMARY
CONFLICT OF INTEREST
AUTHOR CONTRIBUTIONS
REFERENCES

References (0)

[자료제공 : 네이버학술정보]